These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36722447)

  • 1. Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity.
    Trapp CM; Censani M
    Curr Opin Endocrinol Diabetes Obes; 2023 Apr; 30(2):136-140. PubMed ID: 36722447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
    Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
    Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide.
    Wabitsch M; Farooqi S; Flück CE; Bratina N; Mallya UG; Stewart M; Garrison J; van den Akker E; Kühnen P
    J Endocr Soc; 2022 Jun; 6(6):bvac057. PubMed ID: 35528826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the Patient Experience of Hunger and Improved Quality of Life with Setmelanotide Treatment in POMC and LEPR Deficiencies.
    Wabitsch M; Fehnel S; Mallya UG; Sluga-O'Callaghan M; Richardson D; Price M; Kühnen P
    Adv Ther; 2022 Apr; 39(4):1772-1783. PubMed ID: 35192151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Setmelanotide: First Approval.
    Markham A
    Drugs; 2021 Feb; 81(3):397-403. PubMed ID: 33638809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial Effects of Setmelanotide in a 5-Year-Old Boy With POMC Deficiency and on His Caregivers.
    Dubern B; Lourdelle A; Clément K
    JCEM Case Rep; 2023 May; 1(3):luad041. PubMed ID: 37908575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of setmelanotide injection for chronic weight management in adult and pediatric patients with obesity due to Bardet-Biedl syndrome.
    Lazareva J; Brady SM; Yanovski JA
    Expert Opin Pharmacother; 2023 Apr; 24(6):667-674. PubMed ID: 37013719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency.
    Kühnen P; Wabitsch M; von Schnurbein J; Chirila C; Mallya UG; Callahan P; Gnanasakthy A; Poitou C; Krabusch PM; Stewart M; Clément K
    Orphanet J Rare Dis; 2022 Feb; 17(1):38. PubMed ID: 35123544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
    Ayers KL; Glicksberg BS; Garfield AS; Longerich S; White JA; Yang P; Du L; Chittenden TW; Gulcher JR; Roy S; Fiedorek F; Gottesdiener K; Cohen S; North KE; Schadt EE; Li SD; Chen R; Van der Ploeg LHT
    J Clin Endocrinol Metab; 2018 Jul; 103(7):2601-2612. PubMed ID: 29726959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
    Collet TH; Dubern B; Mokrosinski J; Connors H; Keogh JM; Mendes de Oliveira E; Henning E; Poitou-Bernert C; Oppert JM; Tounian P; Marchelli F; Alili R; Le Beyec J; Pépin D; Lacorte JM; Gottesdiener A; Bounds R; Sharma S; Folster C; Henderson B; O'Rahilly S; Stoner E; Gottesdiener K; Panaro BL; Cone RD; Clément K; Farooqi IS; Van der Ploeg LHT
    Mol Metab; 2017 Oct; 6(10):1321-1329. PubMed ID: 29031731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
    Haqq AM; Chung WK; Dollfus H; Haws RM; Martos-Moreno GÁ; Poitou C; Yanovski JA; Mittleman RS; Yuan G; Forsythe E; Clément K; Argente J
    Lancet Diabetes Endocrinol; 2022 Dec; 10(12):859-868. PubMed ID: 36356613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome.
    Ervin C; Norcross L; Mallya UG; Fehnel S; Mittleman RS; Webster M; Haqq AM; Haws RM
    Adv Ther; 2023 May; 40(5):2394-2411. PubMed ID: 36961653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rare genetic forms of obesity: From gene to therapy.
    Clément K; Mosbah H; Poitou C
    Physiol Behav; 2020 Dec; 227():113134. PubMed ID: 32805220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Could setmelanotide be the game-changer for acquired hypothalamic obesity?
    van Santen HM; Denzer C; Müller HL
    Front Endocrinol (Lausanne); 2023; 14():1307889. PubMed ID: 38239988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity.
    Pressley H; Cornelio CK; Adams EN
    J Pharm Technol; 2022 Dec; 38(6):368-373. PubMed ID: 36311304
    [No Abstract]   [Full Text] [Related]  

  • 16. Functional characterization of all missense variants in
    Shah BP; Sleiman PM; Mc Donald J; Moeller IH; Kleyn P
    Expert Rev Endocrinol Metab; 2023 Mar; 18(2):209-219. PubMed ID: 36864747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design.
    Haws RM; Gordon G; Han JC; Yanovski JA; Yuan G; Stewart MW
    Contemp Clin Trials Commun; 2021 Jun; 22():100780. PubMed ID: 34013094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Melanocortin-4 Receptor Agonist Induces Skin and Hair Pigmentation in Patients with Monogenic Mutations in the Leptin-Melanocortin Pathway.
    Kanti V; Puder L; Jahnke I; Krabusch PM; Kottner J; Vogt A; Richter C; Andruck A; Lechner L; Poitou C; Krude H; Gottesdiener K; Clément K; Farooqi IS; Wiegand S; Kühnen P; Blume-Peytavi U
    Skin Pharmacol Physiol; 2021; 34(6):307-316. PubMed ID: 34058738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing of the monogenic obesity genes LEP, LEPR, MC4R, PCSK1 and POMC in a Norwegian cohort of patients with morbid obesity and normal weight controls.
    Nordang GBN; Busk ØL; Tveten K; Hanevik HI; Fell AKM; Hjelmesæth J; Holla ØL; Hertel JK
    Mol Genet Metab; 2017 May; 121(1):51-56. PubMed ID: 28377240
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.